Search by Drug Name or NDC
NDC 16571-0884-10 Allopurinol 200 mg/1 Details
Allopurinol 200 mg/1
Allopurinol is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Rising Pharma Holdings, Inc.. The primary component is ALLOPURINOL.
MedlinePlus Drug Summary
Allopurinol is used to treat gout (a type of arthritis in which uric acid, a naturally occurring substance in the body, builds up in the joints and causes sudden attacks of redness, swelling, pain, and heat in one or more joints). Allopurinol is also used to treat high levels of uric acid that builds up in the blood as tumors break down in people with certain types of cancer who are being treated with chemotherapy medications. It is also used to treat kidney stones that have come back in people who have high levels of uric acid in their urine. Allopurinol is in a class of medications called xanthine oxidase inhibitors. It works by reducing the production of uric acid in the body. High levels of uric acid may cause gout attacks or kidney stones. Allopurinol is used to prevent gout attacks, not to treat them once they occur.
Related Packages: 16571-0884-10Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Allopurinol
Product Information
NDC | 16571-0884 |
---|---|
Product ID | 16571-884_5cd32f4f-2795-4776-ad00-f33f91bda391 |
Associated GPIs | |
GCN Sequence Number | 013173 |
GCN Sequence Number Description | allopurinol TABLET 200 MG ORAL |
HIC3 | C7A |
HIC3 Description | HYPERURICEMIA TX - XANTHINE OXIDASE INHIBITORS |
GCN | 07072 |
HICL Sequence Number | 001100 |
HICL Sequence Number Description | ALLOPURINOL |
Brand/Generic | Generic |
Proprietary Name | Allopurinol |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | allopurinol |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | TABLET |
Route | ORAL |
Active Ingredient Strength | 200 |
Active Ingredient Units | mg/1 |
Substance Name | ALLOPURINOL |
Labeler Name | Rising Pharma Holdings, Inc. |
Pharmaceutical Class | Xanthine Oxidase Inhibitor [EPC], Xanthine Oxidase Inhibitors [MoA] |
DEA Schedule | n/a |
Marketing Category | NDA AUTHORIZED GENERIC |
Application Number | NDA016084 |
Listing Certified Through | 2024-12-31 |
Package
NDC 16571-0884-10 (16571088410)
NDC Package Code | 16571-884-10 |
---|---|
Billing NDC | 16571088410 |
Package | 1000 TABLET in 1 BOTTLE (16571-884-10) |
Marketing Start Date | 2023-09-21 |
NDC Exclude Flag | N |
Pricing Information | N/A |